Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

Explore clinical trials studying Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors trial results

Completed

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

NCT03420742

Conditions
Carcinoma, Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors, Lung Diseases, +8 more
Locations
  • Hopital de la Timone Marseille, Provence-Alpes-Côte d'Azur Region, France
  • Groupe Hospitalier Bichat-Claude Bernard - Hopital Bichat Paris, Île-de-France Region, France
  • Centro di Riferimento Oncologico di Aviano Aviano, Pordenone, Italy
  • Policlinico Sant'Orsola Malpighi Bologna, Italy
View all 14 locations
View Trial Details

Related conditions